• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Anderson Thomas

    5/30/25 9:37:34 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZVRA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Anderson Thomas

    (Last) (First) (Middle)
    C/O ZEVRA THERAPEUTICS, INC.
    1180 CELEBRATION BOULEVARD, SUITE 103

    (Street)
    CELEBRATION FL 34747

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ZEVRA THERAPEUTICS, INC. [ ZVRA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/29/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $8.62(1) 05/29/2025 A 30,000(2) (3) 05/28/2035 Common Stock 30,000 $0 30,000 D
    Explanation of Responses:
    1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 29, 2025.
    2. This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.
    3. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.
    /s/ Timothy J. Sangiovanni, Attorney-in-Fact for Thomas Anderson 05/30/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ZVRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZVRA

    DatePrice TargetRatingAnalyst
    1/8/2025$25.00Overweight
    Cantor Fitzgerald
    10/7/2024$20.00Buy
    Guggenheim
    9/24/2024$17.00Mkt Outperform
    JMP Securities
    9/24/2024$18.00 → $25.00Buy
    Maxim Group
    4/2/2024$12.00 → $18.00Buy
    Maxim Group
    3/12/2024Outperform
    William Blair
    3/17/2023$12.00Buy
    Maxim Group
    More analyst ratings

    $ZVRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Legal & Compliance Thompson Rahsaan sold $221,004 worth of shares (24,000 units at $9.21), decreasing direct ownership by 36% to 42,666 units (SEC Form 4)

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      6/30/25 5:02:34 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal & Compliance Thompson Rahsaan converted options into 66,666 shares (SEC Form 4)

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      6/24/25 5:28:38 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Shih Alvin

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      5/30/25 9:41:56 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Watton Corey Michael bought $2,352 worth of shares (300 units at $7.84), increasing direct ownership by 20% to 1,800 units (SEC Form 4)

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      3/31/25 8:05:01 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bode John B bought $79,624 worth of shares (10,000 units at $7.96), increasing direct ownership by 33% to 40,000 units (SEC Form 4)

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      3/21/25 4:06:49 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Watton Corey Michael bought $3,958 worth of shares (500 units at $7.92), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      10/16/24 4:46:26 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVRA
    SEC Filings

    See more
    • SEC Form 8-K filed by Zevra Therapeutics Inc.

      8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

      5/29/25 4:42:38 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Zevra Therapeutics Inc.

      DEFA14A - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

      5/21/25 4:05:58 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Zevra Therapeutics Inc.

      10-Q - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

      5/13/25 5:15:59 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

      Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the Company's Board of Directors Board and Management Reaffirm Commitment to Driving Continued Growth and Progress Against Strategic Plan CELEBRATION, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) ("Zevra," or the "Company"), a commercial-stage company focused on providing therapies to people living with rare disease, announced that based on the final vote count certified by the independent Inspector of Elections following the Company's 2025 Annual Meeting of Stockholders (the "Annual Meeting"), stockholders have voted to re-elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the

      5/29/25 4:35:32 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

      ISS, Glass Lewis, and Egan-Jones Unanimously Conclude Mangless Has Not Made a Compelling Case for Change Board and Management Urge Stockholders to Follow Proxy Advisors' Recommendation and Vote "FOR" Wendy L. Dixon, Ph.D. and Tamara A. Favorito on the WHITE Proxy Card and "WITHHOLD" for Mangless Nominees CELEBRATION, Fla., May 21, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) ("Zevra," or the "Company"), a commercial-stage company focused on providing therapies to people living with rare disease, today announced that all three leading proxy advisory firms, Institutional Shareholder Services ("ISS"), Glass Lewis & Co. ("Glass Lewis"), and Egan-Jones Proxy Services ("Egan

      5/21/25 7:30:00 AM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zevra Reports First Quarter 2025 Financial Results and Corporate Update

      Q1 2025 net revenue of $20.4 million, driven by product net revenue of $17.2 million Completed sale of PRV for gross proceeds of $150 million, positioning balance sheet to drive the Company's commercial launches and development programs Company to host conference call and webcast today, May 13, 2025, at 4:30 p.m. ET CELEBRATION, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the first quarter ended Mar. 31, 2025. "We are continuing Zevra's transformation into a patient-centric, commercial-

      5/13/25 4:05:00 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care